KDR genetic predictor of toxicities induced by sorafenib and regorafenib.
- Citation:
- Pharmacogenomics J vol 22 (5-6) 251-257
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 12
- Parents:
- 3546
- Children:
- None
- Pharmas:
- Bayer Healthcare/Berlex
- Grants:
- U10CA180821, U10CA180882, U24 CA196171, UG1CA233373, UG1CA233290
- Corr. Author:
- Authors:
- Julia C F Quintanilha Susan Geyer Amy S Etheridge Alessandro Racioppi Kelli Hammond Daniel J Crona Carol E Peña Sawyer B Jacobson Federica Marmorino Daniele Rossini Chiara Cremolini Hanna K Sanoff Ghassan K Abou-Alfa Federico Innocenti
- Networks:
- LAPS-NC007, LAPS-NY016
- Study
- CALGB-80802
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Humans, Sorafenib, Phenylurea Compounds, Pyridines, Neoplasms, Vascular Endothelial Growth Factor Receptor-2